Sandoz, the global leader in generic and biosimilar medicines, today opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely in Europe. The new facility and automated production lines will increase production…
Sandoz has completed the acquisition of the US biosimilar CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product…
Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko® (natalizumab) in Germany from February 1. Developed by Polpharma Biologics, Tyruko® is the first and only biosimilar to treat RRMS. Tyruko® is indicated as a…
Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, for an upfront cash purchase payment of USD 170 million. This agreement is inclusive of a biologics license application, product inventory, ophthalmology sales and…
Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today. Hyrimoz® HCF,…
Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond. The inauguration of a new facility…
Just weeks after our debut as an independent, publicly traded company, Sandoz was named “Company of the Year” in the generics and biosimilar medicines industry. In recognition of his achievements at Sandoz and for the industry as a whole, Sandoz…
Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company. The new company is included in key SIX market indices and has an investment-grade credit…